ESMO26: Standard dosing prevails over 12-week checkpoint inhibitors in MOIO trial
Reduced-frequency checkpoint inhibitor treatment could not demonstrate non-inferior PFS and showed a signal of worse survival.
Reduced-frequency checkpoint inhibitor treatment could not demonstrate non-inferior PFS and showed a signal of worse survival.